Sanofi
Forward trial catalysts linked to SNY
CSA tracks 1 forward catalyst for Sanofi across 1 asset, spanning Phase 3. The nearest is a readout expected Sep 30, 2027 (day precision). Confidence across its tracked catalysts breaks down as 1 medium. Tracked indications include Dermatitis Atopic.
SNY in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Sanofi has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
3 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| amlitelimab | NCT06407934 | Phase 3 | Active, not recruiting | 2026-06-10 | Experimental | Sanofi | Dermatitis Atopic |
| amlitelimab | NCT06241118 catalyst | Phase 3 | Active, not recruiting | 2027-09-30 | Experimental | Sanofi | Dermatitis Atopic |
| amlitelimab | NCT05492578 | Phase 2/3 | Active, not recruiting | 2029-01-22 | Experimental | Sanofi | Dermatitis Atopic |
Every trial the CSA sample links to SNY's tracked assets.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →